Supernus Pharmaceuticals (NASDAQ:SUPN) Stock Price Expected to Rise, Piper Sandler Analyst Says

Supernus Pharmaceuticals (NASDAQ:SUPN) had its price target raised by equities researchers at Piper Sandler from $36.00 to $40.00 in a report issued on Friday,Benzinga reports. The firm currently has a “neutral” rating on the specialty pharmaceutical company’s stock. Piper Sandler’s target price would indicate a potential downside of 11.35% from the stock’s previous close.

A number of other equities analysts also recently commented on the stock. Zacks Research upgraded shares of Supernus Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Tuesday, August 19th. Cantor Fitzgerald increased their price objective on shares of Supernus Pharmaceuticals from $42.00 to $46.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 6th. Finally, Wall Street Zen upgraded shares of Supernus Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Saturday, August 2nd. Two analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat, Supernus Pharmaceuticals currently has an average rating of “Moderate Buy” and an average target price of $43.00.

Supernus Pharmaceuticals Trading Down 0.6%

Shares of NASDAQ SUPN opened at $45.12 on Friday. The firm has a market cap of $2.53 billion, a PE ratio of 39.23 and a beta of 0.74. Supernus Pharmaceuticals has a 1-year low of $29.16 and a 1-year high of $45.60. The company has a fifty day moving average price of $36.63 and a 200 day moving average price of $33.91.

Insiders Place Their Bets

In related news, CEO Jack A. Khattar sold 1,000 shares of the firm’s stock in a transaction dated Monday, August 25th. The shares were sold at an average price of $45.00, for a total value of $45,000.00. Following the completion of the sale, the chief executive officer directly owned 1,071,459 shares in the company, valued at approximately $48,215,655. This trade represents a 0.09% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Bethany Sensenig sold 5,369 shares of the firm’s stock in a transaction dated Thursday, August 14th. The shares were sold at an average price of $42.25, for a total transaction of $226,840.25. The disclosure for this sale can be found here. Insiders sold a total of 179,606 shares of company stock worth $7,617,005 in the last three months. Insiders own 8.80% of the company’s stock.

Institutional Investors Weigh In On Supernus Pharmaceuticals

Hedge funds have recently bought and sold shares of the company. Raiffeisen Bank International AG acquired a new stake in Supernus Pharmaceuticals in the 4th quarter valued at about $25,000. Financial Management Professionals Inc. acquired a new stake in Supernus Pharmaceuticals in the 1st quarter valued at about $30,000. Versant Capital Management Inc raised its holdings in Supernus Pharmaceuticals by 6,931.3% in the 1st quarter. Versant Capital Management Inc now owns 1,125 shares of the specialty pharmaceutical company’s stock valued at $37,000 after acquiring an additional 1,109 shares during the period. GF Fund Management CO. LTD. bought a new position in Supernus Pharmaceuticals in the 4th quarter valued at about $42,000. Finally, Caitong International Asset Management Co. Ltd bought a new position in Supernus Pharmaceuticals in the 1st quarter valued at about $41,000.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.